Posts in Regulatory Affairs

Feed Additives and the EU Union Register

Feed Additives for Pet Products: How Authorisation Works and Why the Union Register Is Your First Check

How to check whether a feed additive is authorised in the EU and what conditions of use apply for pet and animal products.

Food Supplement or Medicine? The Borderline Explained

Food Supplement or Medicine? How the Borderline Is Decided and Why Claims Matter Most

Criteria used in the EU to decide whether a product is a food supplement or a medicinal product, with practical examples.

Mutual Recognition for Food Supplements in the EU

Mutual Recognition for Food Supplements: Selling in Greece and Cyprus a Product Lawful in Another Member State

How Regulation (EU) 2019/515 lets food supplements lawfully sold in one EU country reach another, and where it falls short.

Novel Food or Not? How to Check Your Ingredient

Novel Food or Not? Checking Supplement Ingredients Before Launch in the EU

How to determine whether an ingredient is a novel food in the EU, using the 15 May 1997 cut-off and the Novel Food Catalogue.

Health Claims on Food Supplements (Reg. 1924/2006)

Health Claims on Food Supplements: Regulation (EC) 1924/2006, the Authorised List and the On-Hold Botanical Problem

Which health claims are allowed on food supplements in the EU, how on-hold botanical claims work, and how to stay compliant.

Pet Supplements in the EU: Feed or Medicine?

Pet Supplements in the EU: Complementary Feed, Feed Additives and the Line with Veterinary Medicines

How EU law classifies pet supplements: complementary feed, feed additives or veterinary medicines, and what each route requires.

Food Supplement Registration in Greece & Cyprus

Food Supplement Registration in Greece and Cyprus: Notification, Licensing and Where the Two Systems Differ

How to notify or license a food supplement in Greece (EOF) and Cyprus: routes, timelines and documents. Regulatory guidance from PQRA.

Biosimilars in 2026: EMA Moves Away from the Comparative Efficacy Study

The EMA no longer expects comparative efficacy studies for well-characterised biosimilars. What the tailored clinical approach means for developers.

Choosing Your Route to Market: EU Marketing Authorisation Procedures Explained

For any company bringing a medicine to Europe, one of the earliest and most consequential decisions is procedural rather than scientific: which marketing authorisation route[…]

ATMPs: The Regulatory Path for Advanced Therapies

Cell and gene therapies are among the most promising — and most complex — medicines in development. Advanced therapy medicinal products follow a dedicated regulatory[…]